Retroperitoneal cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Retroperitoneal cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Retifanlimab, Doxorubicin, and Ifosfamide for Adults with Certain Types of Sarcoma in the Abdomen, Limbs, and Trunk https://clinicaltrials.eu/trial/study-on-retifanlimab-doxorubicin-and-ifosfamide-for-adults-with-certain-types-of-sarcoma-in-the-abdomen-limbs-and-trunk/ Wed, 29 Apr 2026 14:59:58 +0000 https://clinicaltrials.eu/trial/study-on-retifanlimab-doxorubicin-and-ifosfamide-for-adults-with-certain-types-of-sarcoma-in-the-abdomen-limbs-and-trunk/ This clinical trial is focused on studying a type of cancer called retroperitoneal sarcoma, which can occur in the area behind the abdominal organs, as well as in the limbs and trunk wall. The study is investigating a treatment that combines a new medication called Retifanlimab (INCMGA00012) with standard chemotherapy drugs, Doxorubicin and Ifosfamide. These medications are given as a solution through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to explore how effective this combination treatment is in reducing the size of the tumor before surgery. Participants in the study will receive the treatment over a period of time, and the response of the tumor will be assessed by examining the tissue removed during surgery. The study will also monitor the safety of the treatment and how long patients remain free from cancer progression or survive after starting the treatment.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their well-being and to track the effects of the treatment. The study aims to provide valuable information on whether adding Retifanlimab to the chemotherapy regimen can improve outcomes for patients with this type of sarcoma. The results will help determine if this combination could become a standard treatment option in the future.

]]> Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer https://clinicaltrials.eu/trial/study-on-olaparib-and-bevacizumab-for-patients-with-advanced-ovarian-fallopian-tube-or-peritoneal-cancer/ Wed, 29 Apr 2026 14:58:06 +0000 https://clinicaltrials.eu/trial/study-on-olaparib-and-bevacizumab-for-patients-with-advanced-ovarian-fallopian-tube-or-peritoneal-cancer/ This clinical trial is focused on studying advanced stages of certain types of cancer, specifically ovarian cancer, fallopian tube cancer, and peritoneal cancer. These cancers are at a high grade and advanced stage, known as FIGO Stage III-IV. The study involves two medications: Olaparib and Bevacizumab. Olaparib, also known by its code name AZD-2281, is a type of medication that inhibits an enzyme called PARP, which is involved in repairing damaged DNA in cells. Bevacizumab, sometimes referred to by code names like BI 695502 or RHUMAB-VEGF, is a humanized monoclonal antibody that works by inhibiting the growth of blood vessels that supply nutrients to tumors.

The purpose of this study is to better understand how these medications can benefit patients with these types of cancers after they have received standard first-line treatment. The study will explore the status of a condition called HRD, which stands for homologous recombination deficiency, a situation where cancer cells are less able to repair DNA damage. Participants will receive Olaparib in combination with Bevacizumab to see if this combination can provide additional benefits. The study is non-randomized and open-label, meaning all participants will know which treatment they are receiving, and it is designed to gather information prospectively, or looking forward in time.

Participants in the study will follow a treatment plan that includes taking Olaparib orally and receiving Bevacizumab through intravenous use. The study will last for a period of time, with regular monitoring to assess the effects of the treatment. The main goal is to determine how well the HRD status can be identified using different tests and to see how this status affects the treatment outcomes. The study will also look at the progression-free survival and overall survival of participants, as well as any side effects experienced during the trial. The trial is expected to continue until 2028.

]]>